Moleculin Biotech 将来の成長

Future 基準チェック /06

Moleculin Biotechは、43.9%と79.1%でそれぞれ年率43.9%で利益と収益が成長すると予測される一方、EPSはgrowで48.2%年率。

主要情報

43.9%

収益成長率

48.2%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	79.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:MOL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-35	-40	-40	3
12/31/2025	N/A	-31	-35	-34	3
12/31/2024	N/A	-26	-28	-28	3
3/31/2024	N/A	-27	-25	-25	N/A
12/31/2023	N/A	-30	-24	-24	N/A
9/30/2023	N/A	-26	-26	-26	N/A
6/30/2023	N/A	-29	-26	-26	N/A
3/31/2023	N/A	-30	-29	-29	N/A
12/31/2022	N/A	-29	-28	-28	N/A
9/30/2022	N/A	-25	-25	-25	N/A
6/30/2022	N/A	-21	-21	-21	N/A
3/31/2022	N/A	-18	-20	-20	N/A
12/31/2021	N/A	-16	-19	-19	N/A
9/30/2021	N/A	-16	-18	-18	N/A
6/30/2021	N/A	-15	-19	-19	N/A
3/31/2021	N/A	-21	-17	-17	N/A
12/31/2020	N/A	-17	-18	-18	N/A
9/30/2020	N/A	-19	-20	-19	N/A
6/30/2020	N/A	-19	-17	-17	N/A
3/31/2020	N/A	-10	-18	-18	N/A
12/31/2019	N/A	-13	-17	-17	N/A
9/30/2019	N/A	-12	-16	-16	N/A
6/30/2019	N/A	-10	-16	-15	N/A
3/31/2019	N/A	-14	-14	-13	N/A
12/31/2018	N/A	-12	-13	-12	N/A
9/30/2018	N/A	-12	-12	-11	N/A
6/30/2018	N/A	-13	-10	-10	N/A
3/31/2018	N/A	-11	-9	-9	N/A
12/31/2017	N/A	-10	N/A	-7	N/A
9/30/2017	N/A	-8	N/A	-6	N/A
6/30/2017	N/A	-7	N/A	-5	N/A
3/31/2017	N/A	-4	N/A	-5	N/A
12/31/2016	N/A	-4	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MOL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MOL今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MOL今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MOL来年は収益がないと予測されています。

高い収益成長: MOL来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MOLの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Moleculin Biotech 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2024

Recent updates

Moleculin Biotech, Inc. Announces New Findings Supporting the Ability of Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Moleculin Biotech, Inc., Annual General Meeting, Oct 24, 2024

Moleculin Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $5.497817 million.

Moleculin Biotech, Inc. Announces Plans for MIRACLE Phase 3 Pivotal Trial

Moleculin Biotech, Inc. has filed a Follow-on Equity Offering.

Moleculin Biotech, Inc. Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)

Moleculin Biotech, Inc. to Report Q1, 2024 Results on May 10, 2024

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman

Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

New major risk - Financial position

Moleculin Biotech, Inc. to Report Fiscal Year 2023 Results on Mar 22, 2024

Moleculin Biotech, Inc. Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding

New major risk - Financial position

Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

Moleculin Biotech, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Moleculin Biotech Receives an Extension of the 180 Calendar Days from Nasdaq to Regain Compliance with the Bid Price Requirement

Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

New major risk - Financial position

Moleculin Biotech, Inc. Provides Update on Ongoing Clinical Trials

Moleculin Biotech, Inc. to Report Q2, 2023 Results on Aug 11, 2023

Moleculin Biotech, Inc., Annual General Meeting, Jun 15, 2023

Moleculin Biotech Receives Non-Compliance Notice From Nasdaq

Moleculin Biotech, Inc. to Report Q1, 2023 Results on May 11, 2023

Moleculin Biotech, Inc. Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Receives FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Founder recently bought €55k worth of stock

Founder recently bought €104k worth of stock

Moleculin Biotech, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Moleculin Biotech, Inc Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces WP1096 Molecule Will Be Evaluated in Animal Studies Through the Preclinical Services Offered by the National Institute of Allergy and Infectious Diseases

Moleculin Biotech, Inc. Announces Completion of Third Single Ascending Dose Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Concludes Phase 1B and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

Moleculin Biotech, Inc. Announces Completion of First Single Ascending Dose (Sad) Cohort in Phase 1A Clinical Trial of Wp1122 in the UK

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc. Announces the Commencement of Dosing in Its First-In-Human Phase 1A Study to Evaluate the Safety and Pharmacokinetics (PK) of Wp1122 in Healthy Volunteers for the Treatment of COVID-19 (MB-301)

Moleculin Biotech, Inc Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Moleculin Biotech, Inc. Receives Allowance to Proceed with Phase 1/2 Study of Annamycin

Moleculin Biotech, Inc. Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Moleculin Biotech, Inc. Receives IND Clearance to Conduct Phase 1 Study of WP1066 for Treatment of Recurrent Malignant Glioma

Moleculin Biotech, Inc., Annual General Meeting, May 26, 2022

Moleculin Biotech, Inc. Announces Presentation of Positive Preclinical Annamycin Data At the AACR 2022 Annual Meeting

Moleculin Biotech, Inc. Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

Moleculin Biotech, Inc. Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc. Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

High number of new and inexperienced directors

High number of new and inexperienced directors

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia

Moleculin Biotech, Inc. Announces First Subject Enrolled and Dosed in Phase 1B/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

Moleculin Biotech, Inc. Commences Phase 1B/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

Forecast to breakeven in 2024

New 90-day high: €5.40

Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

New 90-day high: €0.85

Moleculin Biotech, Inc. Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

Moleculin Biotech, Inc. to Present Antitumor Activity of Annamycin in Combination with Ara-C in AML At American Society for Hematology Annual Conference

Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066

New 90-day high: €0.81

Moleculin Biotech, Inc. Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML

New 90-day low: €0.60

Moleculin Announces Additional Preliminary Data from the Phase 1 Clinical Trial of Its Immuno-Stimulating STAT3 inhibitor, WP1066